Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

NUTRA PHARMA CORP

CIK 1119643 NPHC·Manufacturing · All EDGAR filings ↗

Progression

  1. Going concern 10-K
  2. Late filing NT 10-Q +178d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Late filing Filing comparison

NUTRA PHARMA CORP told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. Filed on the statutory due date.

The Form 10-Q could not be filed within the prescribed time because additional time is required by Registrant’s management and auditors to prepare certain financial information to be included in such report.
Evidence
Anticipates significant change
No
Days past due date
0
Other periodic reports filed
Yes
Routine
Yes
Severity
normal
Source
Form 12b-25 (notification of late filing)
Stated reason
The Form 10-Q could not be filed within the prescribed time because additional time is required by Registrant’s management and auditors to prepare certain financial information to be included in such report.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Going concern Filing comparison

NUTRA PHARMA CORP disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure → Substantial doubt about ability to continue as a going concern

Doubt about the Company’s Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1, the Company has experienced significant recurring losses from operations, had a significant amount of indebtedness in default, and had significant working capital and stockholders’ deficits. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
going-concern note
Prior filed
2026-02-17
Prior form
10-K
Prior state
none
Prior state label
No going-concern disclosure
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Going concern Filing comparison

NUTRA PHARMA CORP no longer discloses a going-concern conclusion

Substantial doubt about ability to continue as a going concern → No going-concern disclosure

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to the ability to continue as a going concern, the recoverability of inventory and long-lived assets, the fair value of stock-based compensation, the fair value of debt, the fair value of derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances are updated as appropriate…
Evidence
Blank check
No
Comparable
Yes
Current state
none
Current state label
No going-concern disclosure
Direction
eased
Located in
filing body
Prior filed
2025-11-24
Prior form
10-K
Prior state
substantial_doubt
Prior state label
Substantial doubt about ability to continue as a going concern
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Accounting standard newly cited Filing comparison

NUTRA PHARMA CORP cited accounting standard ASU 2023-07 for the first time in this filing series

The filing states this standard was adopted in 2024, so this is the first time it has been cited in this series rather than a change of policy in the current period.

… 4,204,072 Convertible notes payable 7,081,149,502 6,612,566,602 Total 27,495,805,699 25,286,770,674 Recent Accounting Pronouncements Adopted Pronouncements As of January 1, 2024, the Company adopted ASU No. 2023-07, Codification Improvements to Segment Reporting (Topic 280) (“ASU 2023-07”), which provides clarifications and improvements to the existing segment reporting requirements, including…
Evidence
Adopted
2023-07
Adoption year stated
2024
Caveat
The filing states this standard was adopted in 2024, so this is the first time it has been cited in this series rather than a change of policy in the current period.
Contexts
… 4,204,072 Convertible notes payable 7,081,149,502 6,612,566,602 Total 27,495,805,699 25,286,770,674 Recent Accounting Pronouncements Adopted Pronouncements As of January 1, 2024, the Company adopted ASU No. 2023-07, Codification Improvements to Segment Reporting (Topic 280) (“ASU 2023-07”), which provides clarifications and improvements to the existing segment reporting requirements, including…
New standards
2023-07, 2024-04, 2025-05
Prior filed
2025-11-24
Prior form
10-K
Restates existing policy
Yes
Source
accounting standards update (ASU) reference comparison
Why
An accounting standard (ASU) appears in this filing that did not appear in the previous comparable one, in a sentence describing it as adopted. That is a change in what the company discloses, which is not always a change of policy in the current period: the filing may state an adoption date years earlier.

Source filing ↗ Prior filing ↗